(1.04%) 5 117.05 points
(1.06%) 38 631 points
(1.84%) 16 133 points
(-0.46%) $78.59
(4.42%) $2.13
(-0.26%) $2 303.60
(-1.13%) $26.53
(-0.06%) $962.00
(-0.47%) $0.928
(-1.42%) $10.84
(-0.21%) $0.796
(0.31%) $91.41
-0.90% KRW 4 390.00
Live Chart Being Loaded With Signals
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China...
Stats | |
---|---|
Volumen de hoy | 47 660.00 |
Volumen promedio | 455 522 |
Capitalización de mercado | 215.19B |
EPS | KRW0 ( 2024-02-13 ) |
Próxima fecha de ganancias | ( KRW0 ) 2024-05-12 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW4.21 (0.10%) |
Volumen Correlación
Helixmith Co., Ltd Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Helixmith Co., Ltd Correlación - Moneda/Commodity
Helixmith Co., Ltd Finanzas
Annual | 2023 |
Ingresos: | KRW4.20B |
Beneficio Bruto: | KRW-8.57B (-204.02 %) |
EPS: | KRW-1 543.76 |
FY | 2023 |
Ingresos: | KRW4.20B |
Beneficio Bruto: | KRW-8.57B (-204.02 %) |
EPS: | KRW-1 543.76 |
FY | 2022 |
Ingresos: | KRW2.80B |
Beneficio Bruto: | KRW-10.03B (-358.20 %) |
EPS: | KRW-1 153.75 |
Financial Reports:
No articles found.
Helixmith Co., Ltd
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico